BNT162b2疫苗诱导产生的针对真实B.1、B.1.1.7、B.1.351、B.1.525和P.1型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的中和抗体血清学调查

Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.

作者信息

Zani Alberto, Caccuri Francesca, Messali Serena, Bonfanti Carlo, Caruso Arnaldo

机构信息

Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

出版信息

Emerg Microbes Infect. 2021 Dec;10(1):1241-1243. doi: 10.1080/22221751.2021.1940305.

DOI:10.1080/22221751.2021.1940305

PMID:34092181

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8216260/

Abstract

In this study, we show that BNT162b2 vaccine-elicited antibodies efficiently neutralize SARS-CoV-2 authentic viruses belonging to B.1, B.1.1.7, B.1.351, B.1.525 and P.1 lineages. Interestingly, the neutralization of B.1.1.7 and B.1.525 lineages was significantly higher, whereas the neutralization of B.1.351 and P.1 lineages was robust but significantly lower as compared to B.1 lineage. Following our findings, we consider that the BNT162b2 vaccine offers protection against the current prevailing variants of SARS-CoV-2.

摘要

在本研究中，我们表明BNT162b2疫苗引发的抗体能够有效中和属于B.1、B.1.1.7、B.1.351、B.1.525和P.1谱系的新冠病毒真实毒株。有趣的是，与B.1谱系相比，BNT162b2疫苗对B.1.1.7和B.1.525谱系的中和能力显著更高，而对B.1.351和P.1谱系的中和能力虽强但显著更低。基于我们的研究结果，我们认为BNT162b2疫苗可提供针对当前流行的新冠病毒变体的保护。